Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 215-216

  Melief, Cornelis J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

Author keywords

cancer vaccine; CD4 T cell; CD8 T cell; human papilloma virus type 16 (HPV16); Montanide ISA 51; peptide vaccine; synthetic vaccine; T lymphocyte; vulvar intraepithelial neoplasia (VIN)

Indexed keywords

BINDING PROTEIN; FREUND ADJUVANT; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1 BINDING PROTEIN; MINERAL OIL; MONTANIDE ISA 51; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANUS CANCER; CANCER IMMUNIZATION; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG POTENCY; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRECANCER; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; VULVA CANCER; VULVAR INTRAEPITHELIAL NEOPLASIA;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RABBITS; UTERINE CERVICAL NEOPLASMS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84858769456     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318248f17f     Document Type: Review

References (13)

1. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360. (Pubitemid 351589701)
2. van der Burg SH, Arens R, Melief CJ. Immunotherapy for persistent viral infections and associated disease. Trends Immunol. 2011;32:97-103.
3. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opinion Immunol. 2011;23:252-257.
4. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119-2127.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl Med. 2010;363:411-422.
6. Zwaveling S, Ferreira MC, Nout J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169:350-358. (Pubitemid 34686155)
7. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine. 2005;23:5271-5280. (Pubitemid 41443433)
8. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in endstage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14169-14177.
9. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-187. (Pubitemid 351377994)
10. Kenter GG, Welters MJP, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
11. Helters MJP, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA. 2010;107:11895-11899.
12. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-383.
13. Khan S, Bijker MS, et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem. 2007; 282:21145-21159. (Pubitemid 47099911)